{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:41:31Z","timestamp":1790505691427,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The SOX4 transcription factor is a key regulator of embryonic development, cell-fate decision, cellular differentiation and oncogenesis. Abnormal expression of SOX4 is related to malignant tumor transformation and cancer metastasis. However, no reports are available regarding the clinical significance of SOX4 in acute myeloid leukemia (AML) and the role of SOX4 in leukemogenesis. In the current study, we found that AML patients with low bone marrow (BM) SOX4 expression had higher remission rates and longer overall survival than those with high SOX4 expression, regardless of age, white blood cell count at diagnosis, karyotype profile and N\n                    <jats:italic>PM1<\/jats:italic>\n                    \/\n                    <jats:italic>FLT3-<\/jats:italic>\n                    ITD status. To elucidate the role of SOX4 in leukemogenesis, we generated a transgenic zebrafish model that overexpressed human\n                    <jats:italic>SOX4<\/jats:italic>\n                    in the myeloid lineage Tg(\n                    <jats:italic>spi1<\/jats:italic>\n                    -\n                    <jats:italic>SOX4<\/jats:italic>\n                    -\n                    <jats:italic>EGFP<\/jats:italic>\n                    ). These transgenic zebrafish showed, at 5 months of age, increased myelopoiesis with dedifferentiation in kidney marrow. At 9 months of age, their kidney structure was significantly effaced and distorted by increased infiltration of myeloid progenitor cells. These results suggest that SOX4 is not only an independent prognostic factor of AML, but also an important molecular factor in leukemogenesis.\n                  <\/jats:p>","DOI":"10.1038\/bcj.2017.74","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T09:22:02Z","timestamp":1503652922000},"page":"e593-e593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish"],"prefix":"10.1038","volume":"7","author":[{"given":"J-W","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-S","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-A","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-F","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L-I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"BFbcj201774_CR1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.biocel.2009.12.004","volume":"42","author":"V Harley","year":"2010","unstructured":"Harley V, Lefebvre V . Twenty Sox, twenty years. Int J Biochem Cell Biol 2010; 42: 376\u2013377.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFbcj201774_CR2","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00018-012-1187-y","volume":"70","author":"SM Jafarnejad","year":"2013","unstructured":"Jafarnejad SM, Ardekani GS, Ghaffari M, Li G . Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci 2013; 70: 2677\u20132696.","journal-title":"Cell Mol Life Sci"},{"key":"BFbcj201774_CR3","doi-asserted-by":"publisher","first-page":"18429","DOI":"10.1074\/jbc.M113.478503","volume":"288","author":"Y Jiang","year":"2013","unstructured":"Jiang Y, Ding Q, Xie X, Libby RT, Lefebvre V, Gan L . Transcription factors SOX4 and SOX11 function redundantly to regulate the development of mouse retinal ganglion cells. J Biol Chem 2013; 288: 18429\u201318438.","journal-title":"J Biol Chem"},{"key":"BFbcj201774_CR4","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1038\/onc.2012.506","volume":"32","author":"SJ Vervoort","year":"2013","unstructured":"Vervoort SJ, van Boxtel R, Coffer PJ . The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene 2013; 32: 3397\u20133409.","journal-title":"Oncogene"},{"key":"BFbcj201774_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/eji.1830270534","volume":"27","author":"MW Schilham","year":"1997","unstructured":"Schilham MW, Moerer P, Cumano A, Clevers HC . Sox-4 facilitates thymocyte differentiation. Eur J Immunol 1997; 27: 1292\u20131295.","journal-title":"Eur J Immunol"},{"key":"BFbcj201774_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1677\/jme.0.0220295","volume":"22","author":"JD Graham","year":"1999","unstructured":"Graham JD, Hunt SM, Tran N, Clarke CL . Regulation of the expression and activity by progestins of a member of the SOX gene family of transcriptional modulators. J Mol Endocrinol 1999; 22: 295\u2013304.","journal-title":"J Mol Endocrinol"},{"key":"BFbcj201774_CR7","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1158\/0008-5472.CAN-05-3456","volume":"66","author":"M Aaboe","year":"2006","unstructured":"Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006; 66: 3434\u20133442.","journal-title":"Cancer Res"},{"key":"BFbcj201774_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/hmg\/ddp034","volume":"18","author":"PP Medina","year":"2009","unstructured":"Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 2009; 18: 1343\u20131352.","journal-title":"Hum Mol Genet"},{"key":"BFbcj201774_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1746-1596-7-41","volume":"7","author":"C Wang","year":"2012","unstructured":"Wang C, Zhao H, Lu J, Yin J, Zang L, Song N et al. Clinicopathological significance of SOX4 expression in primary gallbladder carcinoma. Diagn Pathol 2012; 7: 41.","journal-title":"Diagn Pathol"},{"key":"BFbcj201774_CR10","doi-asserted-by":"publisher","first-page":"e67128","DOI":"10.1371\/journal.pone.0067128","volume":"8","author":"CM Lin","year":"2013","unstructured":"Lin CM, Fang CL, Hseu YC, Chen CL, Wang JW, Hsu SL et al. Clinical and prognostic implications of transcription factor SOX4 in patients with colon cancer. PLoS One 2013; 8: e67128.","journal-title":"PLoS One"},{"key":"BFbcj201774_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/pcan.2013.25","volume":"16","author":"L Wang","year":"2013","unstructured":"Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z et al. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 2013; 16: 301\u2013307.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFbcj201774_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2014.08.124","volume":"452","author":"W Wang","year":"2014","unstructured":"Wang W, Zhang J, Zhan X, Lin T, Yang M, Hu J et al. SOX4 is associated with poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014; 452: 614\u2013621.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbcj201774_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/neup.12212","volume":"35","author":"L Li","year":"2015","unstructured":"Li L, Li Q, Chen X, Xu M, Li X, Nie L et al. SOX4 is overexpressed in diffusely infiltrating astrocytoma and confers poor prognosis. Neuropathology 2015; 35: 510\u2013517.","journal-title":"Neuropathology"},{"key":"BFbcj201774_CR14","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1007\/s13277-014-3026-2","volume":"36","author":"N Lu","year":"2015","unstructured":"Lu N, Lin T, Wang L, Qi M, Liu Z, Dong H et al. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol 2015; 36: 3843\u20133852.","journal-title":"Tumour Biol"},{"key":"BFbcj201774_CR15","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1007\/s13277-015-3051-9","volume":"36","author":"GD Song","year":"2015","unstructured":"Song GD, Sun Y, Shen H, Li W . SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumour Biol 2015; 36: 4167\u20134173.","journal-title":"Tumour Biol"},{"key":"BFbcj201774_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11010-014-2315-9","volume":"402","author":"D Wang","year":"2015","unstructured":"Wang D, Hao T, Pan Y, Qian X, Zhou D . Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer. Mol Cell Biochem 2015; 402: 75\u201382.","journal-title":"Mol Cell Biochem"},{"key":"BFbcj201774_CR17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/sj.leu.2404961","volume":"21","author":"A Tonks","year":"2007","unstructured":"Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21: 2495\u20132505.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/leu.2010.42","volume":"24","author":"ER Yassin","year":"2010","unstructured":"Yassin ER, Abdul-Nabi AM, Takeda A, Yaseen NR . Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif. Leukemia 2010; 24: 1001\u20131011.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2011.057067","volume":"98","author":"N Omidvar","year":"2013","unstructured":"Omidvar N, Maunakea ML, Jones L, Sevcikova S, Yin B, Himmel KL et al. PML-RARalpha co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica 2013; 98: 424\u2013427.","journal-title":"Haematologica"},{"key":"BFbcj201774_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2011-03-341081","volume":"119","author":"Y Huang","year":"2012","unstructured":"Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012; 119: 388\u2013398.","journal-title":"Blood"},{"key":"BFbcj201774_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1182\/blood-2011-05-357418","volume":"120","author":"S Sandoval","year":"2012","unstructured":"Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E et al. Sox4 cooperates with CREB in myeloid transformation. Blood 2012; 120: 155\u2013165.","journal-title":"Blood"},{"key":"BFbcj201774_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood-2003-05-1626","volume":"107","author":"KE Boyd","year":"2006","unstructured":"Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, Jenkins NA et al. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood 2006; 107: 733\u2013741.","journal-title":"Blood"},{"key":"BFbcj201774_CR23","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1182\/blood-2011-04-351528","volume":"118","author":"G Aue","year":"2011","unstructured":"Aue G, Du Y, Cleveland SM, Smith SB, Dave UP, Liu D et al. Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood 2011; 118: 4674\u20134681.","journal-title":"Blood"},{"key":"BFbcj201774_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/380711a0","volume":"380","author":"MW Schilham","year":"1996","unstructured":"Schilham MW, Oosterwegel MA, Moerer P, Ya J, de Boer PA, van de Wetering M et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996; 380: 711\u2013714.","journal-title":"Nature"},{"key":"BFbcj201774_CR25","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2004-12-4840","volume":"106","author":"Y Du","year":"2005","unstructured":"Du Y, Spence SE, Jenkins NA, Copeland NG . Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 2005; 106: 2498\u20132505.","journal-title":"Blood"},{"key":"BFbcj201774_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2013.09.018","volume":"24","author":"H Zhang","year":"2013","unstructured":"Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A et al. Sox4 is a key oncogenic target in C\/EBPalpha mutant acute myeloid leukemia. Cancer Cell 2013; 24: 575\u2013588.","journal-title":"Cancer Cell"},{"key":"BFbcj201774_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccr.2013.10.016","volume":"24","author":"TK Fung","year":"2013","unstructured":"Fung TK, Leung AY, So CW . Sox4you: a new player in C\/EBPalpha leukemia. Cancer Cell 2013; 24: 557\u2013559.","journal-title":"Cancer Cell"},{"key":"BFbcj201774_CR28","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/leu.2016.98","volume":"30","author":"C Tregnago","year":"2016","unstructured":"Tregnago C, Manara E, Zampini M, Bisio V, Borga C, Bresolin S et al. CREB engages C\/EBPdelta to initiate leukemogenesis. Leukemia 2016; 30: 1887\u20131896.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR29","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/leu.2016.132","volume":"30","author":"JW Lu","year":"2016","unstructured":"Lu JW, Hou HA, Hsieh MS, Tien HF, Lin LI . Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish. Leukemia 2016; 30: 2098\u20132101.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/leu.2016.170","volume":"31","author":"W Liu","year":"2017","unstructured":"Liu W, Wu M, Huang Z, Lian J, Chen J, Wang T et al. c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish. Leukemia 2017; 31: 222\u2013233.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR31","first-page":"641475","volume":"2015","author":"JW Lu","year":"2015","unstructured":"Lu JW, Hsieh MS, Liao HA, Yang YJ, Ho YJ, Lin LI . Zebrafish as a model for the study of human myeloid malignancies. Biomed Res Int 2015; 2015: 641475.","journal-title":"Biomed Res Int"},{"key":"BFbcj201774_CR32","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1182\/blood-2013-02-486688","volume":"123","author":"BL He","year":"2014","unstructured":"He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC et al. Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood 2014; 123: 2518\u20132529.","journal-title":"Blood"},{"key":"BFbcj201774_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.leukres.2007.08.010","volume":"32","author":"HA Hou","year":"2008","unstructured":"Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008; 32: 904\u2013912.","journal-title":"Leuk Res"},{"key":"BFbcj201774_CR34","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1002\/dvdy.21343","volume":"236","author":"KM Kwan","year":"2007","unstructured":"Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS et al. The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn 2007; 236: 3088\u20133099.","journal-title":"Dev Dyn"},{"key":"BFbcj201774_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2007-06-095398","volume":"111","author":"D Le Guyader","year":"2008","unstructured":"Le Guyader D, Redd MJ, Colucci-Guyon E, Murayama E, Kissa K, Briolat V et al. Origins and unconventional behavior of neutrophils in developing zebrafish. Blood 2008; 111: 132\u2013141.","journal-title":"Blood"},{"key":"BFbcj201774_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/leu.2013.236","volume":"28","author":"HA Hou","year":"2014","unstructured":"Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014; 28: 50\u201358.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2016.65","volume":"30","author":"CH Tsai","year":"2016","unstructured":"Tsai CH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 2016; 30: 1485\u20131492.","journal-title":"Leukemia"},{"key":"BFbcj201774_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/sj.bjc.6605207","volume":"101","author":"HA Hou","year":"2009","unstructured":"Hou HA, Lin LI, Chen CY, Tien HF . Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer 2009; 101: 738\u2013740.","journal-title":"Br J Cancer"},{"key":"BFbcj201774_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2010.222","volume":"25","author":"TC Lin","year":"2011","unstructured":"Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, Tien HF et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 2011; 25: 32\u201340.","journal-title":"Leukemia"},{"issue":"3 Suppl","key":"BFbcj201774_CR40","first-page":"717","volume":"54","author":"C Poiana","year":"2013","unstructured":"Poiana C, Neamtu MC, Avramescu ET, Carsote M, Trifanescu R, Terzea D et al. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol 2013; 54 (3 Suppl): 717\u2013720.","journal-title":"Rom J Morphol Embryol"},{"key":"BFbcj201774_CR41","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","volume":"100","author":"C Preudhomme","year":"2002","unstructured":"Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717\u20132723.","journal-title":"Blood"},{"key":"BFbcj201774_CR42","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","volume":"113","author":"BJ Wouters","year":"2009","unstructured":"Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R . Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088\u20133091.","journal-title":"Blood"},{"key":"BFbcj201774_CR43","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1158\/0008-5472.CAN-11-0176","volume":"71","author":"BT Kvinlaug","year":"2011","unstructured":"Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 2011; 71: 4117\u20134129.","journal-title":"Cancer Res"},{"key":"BFbcj201774_CR44","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173\u20134179.","journal-title":"Cancer Res"},{"key":"BFbcj201774_CR45","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322\u20132333.","journal-title":"Blood"},{"key":"BFbcj201774_CR46","first-page":"3074","volume":"93","author":"H Kiyoi","year":"1999","unstructured":"Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074\u20133080.","journal-title":"Blood"},{"key":"BFbcj201774_CR47","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.18632\/oncotarget.6551","volume":"7","author":"G Song","year":"2016","unstructured":"Song G, Shi L, Guo Y, Yu L, Wang L, Zhang X et al. A novel PAD4\/SOX4\/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells. Oncotarget 2016; 7: 3144\u20133157.","journal-title":"Oncotarget"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201774","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201774.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T12:28:53Z","timestamp":1671712133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8]]}},"alternative-id":["BFbcj201774"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.74","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"assertion":[{"value":"5 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}